Using spinal nalbuphine for pain relief after hip surgery
The Effect of Nalbuphine as an Adjuvant to Levobupivacaine in Subarachnoid Anesthesia in Total Hip Arthroplasty. A Double-blind, Randomized, Controlled Study.
This study tests if adding nalbuphine to a common pain medication helps people feel less pain and use less morphine after hip surgery.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Asklepieion Voulas General Hospital Government |
| Locations | 1 site (Athens, Ελλάδα (+30)) |
| Trial ID | NCT06577155 on ClinicalTrials.gov |
What this trial studies
This clinical trial involves 60 patients undergoing total hip arthroplasty who are randomly assigned to receive either levobupivacaine alone or levobupivacaine combined with nalbuphine for pain management. The study aims to evaluate the effectiveness of these two analgesic regimens by measuring morphine consumption and pain scores at various intervals post-surgery. Additionally, patient satisfaction, complications, and duration of hospitalization will be recorded to assess overall outcomes. The trial employs a standardized multimodal analgesic approach to enhance postoperative pain control.
Who should consider this trial
Good fit: Ideal candidates for this study are patients classified as ASA I-III who are scheduled for total hip arthroplasty.
Not a fit: Patients with a BMI above 40, serious psychiatric disorders, or contraindications for nerve blockade may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved pain management strategies for patients undergoing total hip arthroplasty.
How similar studies have performed: Other studies have shown promising results with similar analgesic approaches, suggesting potential for success in this trial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Physical status according to American Society of Anesthesiologists (ASA) I-III * Patients scheduled for total hip arthroplasty Exclusion Criteria: * BMI above 40 * Serious psychiatric, mental and cognitive disorders * Contraindication for central and/or peripheral nervous blockade * History of allergic or other adverse reactions on the agents used in the study * Chronic opioid
Where this trial is running
Athens, Ελλάδα (+30)
- Asklepieion Hospital of Voula — Athens, Ελλάδα (+30), Greece (Recruiting)
Study contacts
- Study coordinator: Anastasios Mpontozis
- Email: mpontozis405@gmail.com
- Phone: +306938709796
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.